Mechanism-Based Inactivation of CYP2B1 and Its F-Helix Mutant by Two tert-Butyl Acetylenic Compounds: Covalent Modification of Prosthetic Heme Versus Apoprotein

Hsia-lien Lin, Haoming Zhang, Kathleen R. Noon, and Paul F. Hollenberg

Department of Pharmacology, University of Michigan, Ann Arbor, Michigan

Received July 15, 2009; accepted August 20, 2009

ABSTRACT

The mechanism-based inactivation of cytochrome CYP2B1 [wild type (WT)] and its Thr205 to Ala mutant (T205A) by tert-butylphenylacetylene (BPA) and tert-butyl 1-methyl-2-propynyl ether (BMP) in the reconstituted system was investigated. The inactivation of WT by BPA exhibited a $k_{\text{inact}}/K_I$ value of 1343 min $^{-1}$mM $^{-1}$ and a partition ratio of 1. The inactivation of WT by BMP exhibited a $k_{\text{inact}}/K_I$ value of 33 min $^{-1}$mM $^{-1}$ and a partition ratio of 10. Liquid chromatography/tandem mass spectrometry analysis (LC/MS/MS) of the WT revealed 1) inactivation by BPA resulted in the formation of a protein adduct with a mass increase equivalent to the mass of BPA plus one oxygen atom, and 2) inactivation by BMP resulted in the formation of multiple heme adducts that all exhibited a mass increase equivalent to BMP plus one oxygen atom. LC/MS/MS analysis indicated the formation of glutathione (GSH) conjugates by the reaction of GSH with the ethynyl moiety of BMP or BPA with the oxygen being added to the internal or terminal carbon. For the inactivation of T205A by BPA and BMP, the $k_{\text{inact}}/K_I$ values were suppressed by 100- and 4-fold, respectively, and the partition ratios were increased 9- and 3.5-fold, respectively. Only one major heme adduct was detected following the inactivation of the T205A by BMP. These results show that the Thr205 in the F-helix plays an important role in the efficiency of the mechanism-based inactivation of CYP2B1 by BPA and BMP. Homology modeling and substrate docking studies were presented to facilitate the interpretation of the experimental results.

Received July 15, 2009; accepted August 20, 2009

The cytochrome P450 (P450) 2B enzymes catalyze the metabolism of a wide variety of endogenous and exogenous substrates, including clinically used drugs, chemical carcinogens, steroids, and environmental pollutants. In the past 5 years the crystal structures of ligand-free, 4-(4-chlorophenyl)imidazole-bound, and bifonazole-bound CYP2B4 have revealed that conformational changes in several regions of CYP2B4 can dramatically reshape the active site of the enzyme to fit the size and shape of the bound ligand (Scott et al., 2003, 2004; Zhao et al., 2006). With ligand-bound, the F-G region of CYP2B4 further stabilizes the closed conformation by capping the active site on top of B-helix or forms a crystallographic dimer in which the F-G region of one molecule inserts into the widely open active site cleft of the symmetrically related molecule and vice versa. In the CYPBM3-substrate complex, the F-G region exhibits a rocking motion with the I-helix as a fulcrum in the substrate-docking region to position the substrate for catalysis (Haines et al., 2001). Thus, it appears that the F-helix residues may be prime targets to study to gain information about the relationship between the structure and function of these proteins. The contributions of several amino acids in the F-helix to substrate specificity and the regio- and stereoselectivity of product formation have been shown for members of the CYP2 family (Lindberg and Negishi, 1989; Domanski and Halpert, 2001; Kirton et al., 2002; Guengerich et al., 2003; Lin et al., 2003, 2004; Spatzenegger et al., 2003). The combination of approaches involving mechanism-based inactivators and site-directed mutagenesis has played an important role in studies on the structure-function relationships of P450s, in particular P450 2B (Zhao and Halpert, 2007). Although the efficiency of inactivation by 2-ethynylnaphthalene and 17α-ethynylestradiol is not significantly altered in the Thr205 to Ala (T205A) mutant of CYP2B1, the regioselectivity for the formation of metabolites of testosterone, androstenedione,
and 17α-ethynylestradiol by the T205A mutant is different from that of wild type (WT) (Lin et al., 2003, 2004), suggesting that the functional role of a given residue may be substrate-dependent. Therefore, we investigated the inactivation of WT CYP2B1 and its T205A mutant by 4-tert-butylphenylacetylene (BPA) and tert-butyl 1-methyl-2-propynyl ether (BMP). These two tert-butyl acetylenic compounds are structurally related, as shown in Fig. 1.

BMP has been shown to cause mechanism-based inactivation of CYP2B1 as a result of loss of prosthetic heme with the concomitant formation of heme adducts (von Weymarn et al., 2004). Previous studies on P450s purified from phenobarbital-induced rat liver have shown that catalytic activity is lost in an NADPH- and time-dependent manner when they are incubated with several substituted phenylacetylens and that the mechanism of inactivation involved heme alkylation (Komives and Ortiz de Montellano, 1987). However, inactivation by a phenylacetylene such as BPA having a tert-butyl group has not yet been characterized. Therefore, we have characterized the mechanism-based inactivation of the WT CYP2B1 and the T205A mutant by these two tert-butyl acetylenic compounds. By comparing the WT and mutant P450s, a possible role for the Thr residue at position 205 in the metabolism of these two acetylenes has been identified.

The covalent binding of ethynyl compounds to the prosthetic heme moiety or to the apoprotein has been shown previously (Ortiz de Montellano and Komives, 1985; CaJacob et al., 1988; Chan et al., 1993). Whether the inactivation results from alkylation of the prosthetic heme or modification of the apoprotein appears to be determined by the site of addition of the oxygen at either the internal or terminal carbon of the carbon-carbon triple bond, respectively. Covalent binding of the reactive intermediate to both the heme moiety and the apoprotein has been shown for the inactivation of CYP3A4 and CYP3A5 by 17α-ethynylestradiol (Lin et al., 2002; Lin and Hollenberg, 2007). However, the factors determining which carbon of the triple bond the oxygen is added to are not clear. It is interesting to note that these two structurally related tert-butyl acetylenic compounds inactivate CYP2B1 by two distinct mechanisms and that the efficiency of inactivation by BPA is 70-fold greater than that by BMP. Moreover, when Ala was substituted for Thr at position 205, the decrease of the efficiency of inactivation by BPA and BMP was 100- and 4-fold, respectively. In short, Thr205 is much more critical for the inactivation of CYP2B1 by BPA than for the inactivation by BMP. Homology modeling and docking studies of these two acetylenes in the CYP2B1 active site support the experimental results.

**Materials and Methods**

**Chemicals.** Catalase, NADPH, glutathione (GSH), dilauroyl-1-α-phosphatidylcholine (DLPC), BMP, and BPA were purchased from Sigma-Aldrich (St. Louis, MO). 7-Ethoxy-4-(trifluoromethyl)coumarin (EFC) was from Invitrogen (Carlsbad, CA). All the other chemicals and solvents were of the highest purity available from commercial sources.

**Purification of Enzymes.** The site-specific mutation of Thr205 to Ala in CYP2B1 and the purification of the P450s were performed as described previously (Lin et al., 2003). Reductase was expressed in *Escherichia coli* and purified according to previous published procedures (Lin et al., 2003).

**Enzyme Assay and Inactivation of P450s.** To assess catalytic activity, the purified P450s and reductase were reconstituted with DLPC at 22°C for 30 min as described previously (Lin et al., 2004). The primary reaction mixture contained 500 pmol of P450, 500 pmol of reductase, 50 μg of DLPC, 2 mM GSH, 100 units of catalase, and BMP (3–50 μM) or BPA (0.3–25 μM) in 500 μl of 100 mM potassium phosphate buffer, pH 7.7. After incubation of the primary reaction in the presence of 1 mM NADPH at 22°C with BMP or BPA for the time indicated (0.5–6 min), a 10-μl aliquot was removed and added to 1 ml of a secondary reaction mixture containing 100 μM EFC and 200 μM NADPH. Measurements of catalytic activity and calculations of kinetic values for mechanism-based inactivation were performed as described previously (Kent et al., 2002; Lin et al., 2004).

**Determination of the Partition Ratios.** BMP at concentrations ranging from 2.5 to 300 μM or BPA at concentrations ranging from 0.6 to 100 μM was added to the primary reaction mixture containing 1 μM P450. The reactions were initiated by the addition of 1 mM NADPH and incubated at 22°C for 30 min to allow the inactivation to go to completion (Silverman, 1996). Aliquots were removed and assayed for residual EFC activity as described above.

**High-Pressure Liquid Chromatography Analysis of the Heme Adducts.** A high-pressure liquid chromatography (HPLC) system with a Waters (Milford, MA) 600E system controller was used to investigate the loss of native heme and the formation of heme adducts. Aliquots containing 100 pmol of control (+NADPH) and inactivated (+NADPH) P450, incubated with 10 μM BPA or 25 μM BMP for 5 min as described above for the inactivation, were then analyzed using a C4 reverse-phase column (5 μm, 4.6 x 250 mm, 300 Å; Phenomenex, Torrance, CA). The solvent system consisted of solvent A [0.1% trifluoroacetic acid (TFA) in water] and solvent B (0.05% TFA in acetonitrile). The column was eluted with a linear gradient from 30% to 80% B over 30 min at a flow rate of 1 ml/min, and the column eluant was monitored at 405 nm.

**Electrospray Ionization/Liquid Chromatography/Mass Spectrometry Analysis of the Apoprotein.** The control (+NADPH) and samples inactivated (+NADPH) by incubation with 10 μM BPA for 2 min or 50 μM BMP for 10 min were prepared. Aliquots (originally containing 50 pmol of P450) were analyzed on a C3 reverse-phase column (Zorbax 300SB-C3, 3.5 μm, 3.0 x 150 mm; Agilent Technologies, Wilmington, DE) equilibrated with 40% acetonitrile and 0.1% TFA. After 5 min, the column effluent was directed into the mass...
from the initial plots. The EFC de-ethylation activity as described under was incubated with 3.1
and in Fig. 2.
spectra were recorded. The separate the components of the reconstitution mixture, and the mass
analyzer of an LCQ mass spectrometer (Thermo Fisher Scientific, San
Jose, CA) as described previously (Kent et al., 2006). The acetonitrile
analyzer was set at 30 arbitrary units; the spray voltage was 4.2 kV; and the
conditions were sheath gas set at 90 arbitrary units; the auxiliary gas
(Termo Fisher Scientific). The electrospray ionization (ESI) source
envelopes for the P450s were deconvoluted to give the masses associ-
Luna, 3 µm, 4.6 × 100 mm; Phenomenex) using a gradient of 20 to 30% B over 5 min followed by a gradient to 40% B over 15 min and then increasing linearly to 90% B over 15 min at a flow rate of 0.3 ml/min. The column effluent was directed into the ESI source of an LCQ mass spectrometer (Thermo Fisher Scientific). The ESI conditions were sheath gas flow rate, 90 arbitrary units; auxiliary gas, 30 arbitrary units; spray voltage, 4.5 kV; capillary temperature, 170°C; capillary voltage, 30 V; and tube lens offset, 25 V. Data were acquired in positive ion mode using Xcalibur software (Thermo Fisher Scientific) with one full scan followed by two data-dependent scans of the most intense and the second most intense ions.

Liquid Chromatography/Tandem Mass Spectrometry Analysis of Heme Adducts. The purified P450s and reductase were reconstituted as described previously. Samples containing 50 pmol of CYP2B1, 50 pmol of reductase, 2.5 µg of DLPC, 2 mM GSH, 5 units of catalase, and 1 mM NADPH were incubated with 50 µM BPA at 22°C for 20 min and then subjected to liquid chromatography/tan-
dem mass spectrometry (LC/MS/MS) analysis. Experiments were carried out using a Thermo Fisher Scientific LTQ linear ion trap mass spectrometer equipped with the Thermo Fisher Scientific Surveyor HPLC system. The ESI source was tuned with the heme moiety from horse heart myoglobin to optimize the conditions. The source parameters were 4 kV for the spray voltage, 300°C for the capillary temperature, 47 V for the capillary voltage, 100 V for the tube lens, 30 for the sheath gas, and 5 for the auxiliary gas. The ion trap was operated in the positive ion mode. An aliquot (25 pmol) of the primary reaction mixtures inactivated by incubation with BMP was injected onto a reverse-phase HPLC column (XTerra MS C18, 2.1 × 150 mm; Waters) equilibrated with 60% solvent A (0.1% acetic acid in H2O) and solvent B (0.1% acetic acid in acetonitrile). The samples were analyzed on a C18 reverse-phase column (Luna, 3 µm, 4.6 × 100 mm; Phenomenex) using a gradient of 20 to 30% B over 5 min followed by a gradient to 40% B over 15 min and then increasing linearly to 90% B over 15 min at a flow rate of 0.3 ml/min. The column effluent was directed into the ESI source of an LCQ mass spectrometer (Thermo Fisher Scientific). The ESI source was tuned with the heme moiety from horse heart myoglobin to optimize the conditions. The source parameters were 4 kV for the spray voltage, 300°C for the capillary temperature, 47 V for the capillary voltage, 100 V for the tube lens, 30 for the sheath gas, and 5 for the auxiliary gas. The ion trap was operated in the positive ion mode. An aliquot (25 pmol) of the primary reaction mixtures inactivated by incubation with BMP was injected onto a reverse-phase HPLC column (XTerra MS C18, 2.1 × 150 mm; Waters) equilibrated with 60% solvent A (0.1% acetic acid in H2O) and solvent B (0.1% acetic acid in acetonitrile) at a flow rate of 0.3 ml/min. The column was held at 35% solvent B for 5 min, increased linearly to 80% solvent B over 40 min, then ramped to 95% solvent B over 10 min. The effluent from
the HPLC was directed into the ESI probe of the ion trap. Full-scan data were collected from m/z 300 to 2000, and MS/MS spectra were acquired in a data-dependent mode on the six most abundant ions in the survey scan. The normalized collision energy was set to 35%.

**Docking of Substrates in the CYP2B1 Active Site.** BPA and BMP were docked into the active site of CYP2B1 using the energy-based docking software of AutoDock (version 4.0) (Morris et al., 1996). A homology model of CYP2B1 was constructed based on a template of the CYP2B4 crystal structure (Protein Data Bank code 1SUO) (Scott et al., 2004). The coordinates for BPA and BMP were built using ChemBioOffice 2008 (CambridgeSoft Corporation, Cambridge, MA), and their lowest energy conformations were obtained using the AM1 method. The flexible BPA and BMP ligands were docked to the rigid CYP2B1 using the Lamarckian genetic algorithm approach of AutoDock 4 with the following parameters: mutation rate = 0.02; crossover = 0.80; maximal number of generations = $2.7 \times 10^7$; local search frequency = 0.06.

**Results**

**Inactivation of P450s.** The inactivation of the EFC deethylation activity of the WT and T205A mutant P450s by BPA and BMP was measured using various concentrations of the acetylenic substrates and various time points at each concentration. The inactivation of WT CY2B1 and T205A mutant by BPA was time- and concentration-dependent (Fig. 2). Linear regression analysis of the time course data was used to estimate the initial rate constants ($k_{obs}$) for the inactivation of the P450s by BPA. From the double reciprocal plots (inset) of the values for $k_{obs}$ and the concentration of BPA, the kinetic values for the $K_I$ and $k_{inact}$ were calculated essentially as described previously, and the efficiency of inactivation is expressed as $k_{inact}/K_I$ (Roberts et al., 1998; Kent et al., 2002; Lin et al., 2004). Similar results were observed for the inactivation of the WT and mutant enzymes by BMP (data not shown). All of the kinetic values are summarized in Table 1. BPA is $70$-fold (2343 versus 33) more efficient for the inactivation of the WT enzyme than BMP. For the Thr205 to Ala mutant, the $k_{inact}$ was altered 4-fold, but not the $K_I$ for the inactivation by BMP, whereas both the $K_I$ and $k_{inact}$ were markedly altered for inactivation by BPA. Thus, the mutation of Thr to Ala resulted in an $100$-fold (2343 versus 23) decrease in the efficiency of inactivation by BPA and only $4$-fold (33 versus 9) by BMP.

**Partition Ratios for the Inactivations.** The P450s were incubated with various concentrations of BPA or BMP for 30 min for the inactivation to reach completion. The percentage of activity remaining was plotted as a function of the molar ratio of inactivator to P450 (Fig. 3). The turnover number (partition ratio + 1) was estimated from the intercept of the linear regression line obtained from the lower ratios of each inactivator to the P450s and the straight line obtained from higher ratios of each inactivator to the P450s.
Changes in the Prosthetic Heme Moiety. The reaction mixtures containing the WT or T205A mutant P450s were incubated with 10 μM BPA or 50 μM BMP for 5 min in the absence (WT/control and T205A/control) or presence of NADPH (WT/BPA, WT/BMP, T205A/BPA, and T205A/BMP). As shown in Fig. 4, the samples were analyzed by HPLC, and the elution profiles were monitored at 405 nm for native heme remaining (eluting at 20 min) and the formation of heme adduct peak 1 (eluting at 24 min) and heme adduct peak 2 (eluting at 26 min). For WT/BMP, the native heme remaining and EFC catalytic activity remaining is ~20 and ~24% of WT/control, respectively. For T205A/BMP, the native heme remaining and EFC catalytic activity remaining is ~43 and ~42% of T205A/control, respectively. In contrast, there was no significant loss of native heme for WT/BPA and T205A/BPA when EFC catalytic activity remaining was only ~5 and ~24% with respect to their controls, respectively. These results indicate that heme destruction is the major contributor to the inactivation of both WT and T205A by BMP but not by BPA.

For WT/BMP, the absorbance of native heme, peak 1, and
peak 2 is ~20, ~10, and ~22% of the WT/control, respectively. For T205A/BMP, the absorbance of native heme, peak 1, and peak 2 is ~43, ~1, and ~14% of the T205A/control. These results indicate that substitution of the Thr at the position 205 with Ala attenuated the destruction of native heme and selectively abolished the formation of peak 1.

**LC/MS/MS Analysis of the Heme Adducts Formed with BMP.** It appears that the heme adduct peak 1 shown in Fig. 4A was not a single homogeneous peak. Therefore, we used LC/MS/MS analysis with a high-resolution HPLC column to further characterize the masses of the heme adducts. Figure 5A shows that four major (a, b, c, and f) and two minor (d and e) heme-derived peaks were now detected in the HPLC profile when monitoring the absorbance at 405 nm after inactivation of CYP2B1 by BMP. The maximal photodiode-array absorption spectra of peak a, peak b/c, peak d/e, and peak f were at 398, 411, 402, and 405 nm, respectively (data not shown). Figure 5B shows the following: 1) the extracted ion chromatogram for peak a with the MH+ ion at m/z 616.2 is that of the native heme; 2) the extracted ion chromatograms for peaks b, c, and f with MH+ ions at m/z 705.5 are the equivalent of alkylation of the Fe-free prosthetic heme by BMP plus one oxygen atom; and 3) the extracted ion chromatograms for peaks d and e with MH+ ions at m/z 758.5 are the equivalent of alkylation of the Fe-containing prosthetic heme by BMP plus one oxygen atom. The full mass spectra for the native heme, Fe-free heme adducts with precursor ions at m/z 705.5 and the Fe-containing heme adducts with precursor ions at m/z 758.5 are displayed in Fig. 5C. The MS/MS spectra of the major heme adduct with ions at m/z 705.5 have previously been reported (von Weymarn et al., 2004). The heme adducts with MH+ ions at m/z 758.5 were not abundant, and their analysis was hampered by the presence of coeluting reductase.

**Characterization of the Apoprotein Adduct by ESI/LC/MS Analysis.** The P450 reaction mixtures were incubated with BPA or BMP in the absence (control) or presence (inactivated) of NADPH, and then analyzed by ESI/LC/MS.
Portions of the reaction mixtures were analyzed for EFC de-ethylation activity, and ~10% of the catalytic activity remained after the inactivation by either BPA or BMP. Figure 6A shows the unmodified CYP2B1 apoprotein with a mass of ~55,885 Da. Figure 6B shows the BPA-inactivated CYP2B1 apoprotein with the predominant mass of ~56,059 Da and a trace amount of unmodified protein with a mass of ~55,885 Da. The difference in the mass of ~174 Da is consistent with the addition of the mass of one BPA molecule plus one oxygen atom. In contrast, under the same conditions, Fig. 6C shows that the mass of BMP-inactivated CYP2B1 apoprotein remains at ~55,885 Da, which is identical to that of the unmodified apoprotein. For the T205A apoprotein, a mass increase of ~174 Da was also observed after the inactivation by BPA, but no changes were observed after inactivation by BMP (data not shown). Therefore, CYP2B1 WT and the T205A mutant are inactivated by BPA, but not by BMP, via adduction to apoprotein.

**LC/MS/MS Analysis of GSH Conjugates of BPA and BMP.** One approach used to identify reactive intermediates formed during metabolism by P450s involves trapping the intermediates by reaction with GSH and then elucidating the structures of the GSH conjugates by LC/MS/MS. Our laboratory has previously used this approach to identify the GSH conjugates formed during the inactivation of various P450s by a variety of ethynyl inactivators (Kent et al., 2006; Lin and Hollenberg, 2007; Sridar et al., 2008). Therefore, the formation of GSH conjugates during the inactivation of WT and T205A CYP2B1 by BPA and BMP was investigated.

The extracted ion chromatogram of a GSH conjugate eluting at 25.8 min with a precursor ion at m/z 482 is shown in Fig. 7A. This conjugate was observed during the inactivation of the WT and T205A mutant by BPA. The molecular mass of the GSH conjugate corresponds to the sum of the mass of GSH (307 Da) plus BPA (158 Da) and one oxygen atom. The MS/MS spectrum shown in Fig. 7B exhibits a fragment ion at m/z 407 from the loss of Gly (75 Da); the fragment ion at m/z 353 is from loss of Glu (129 Da); and the further loss of water forms the ion at m/z 335 (Baillie and Davis, 1993). The ion at m/z 278 is from a combination of the loss of Glu and Gly, and...
the further loss of CO produces the fragment ion at \( m/z \) 250. All the fragment ions indicate that GSH is a component of the BPA-GSH conjugate at \( m/z \) 482. The ion at \( m/z \) 205 results from the cleavage of the C-S bond within the GSH moiety. However, whether the oxygen has been added to the internal or terminal carbon cannot be ascertained from the MS/MS spectrum. Ortiz de Montellano et al., (1982) have previously reported that if the oxygen atom is added to the internal carbon, the heme will be alkylated, and if the oxygen is added to the terminal carbon, the protein will be modified (Ortiz de Montellano and Komives, 1985; CaJacob et al., 1988; Chan et al., 1993). Because a protein adduct was identified in this case, the structure proposed for the GSH conjugate has the oxygen inserted into the terminal carbon as shown in Fig. 7C.

The mass increase of 174 Da for the BPA-GSH conjugate is equivalent to the mass of BPA plus one oxygen and is identical to the mass increase of the apoprotein adduct in the inactivated P450, indicating that the same reactive species forming the GSH conjugate covalently binds with the P450 apoprotein.

The extracted ion chromatograms for the two GSH conjugates with precursor ions at \( m/z \) 450 formed in incubations of BMP with WT CYP2B1 are shown in Fig. 8A. Similar results were observed on incubations of BMP with the T205A mutant, except the relative intensity of the two conjugates was almost identical (data not shown). The molecular mass of these two GSH conjugates corresponds to the sum of the mass of BMP plus one oxygen atom and GSH. The MS/MS spectra of the conjugates that eluted at 11.9 and 13.5 min are displayed in Fig. 8, B and C, respectively. For both GSH conjugates, the major fragment ion at \( m/z \) 394 is from the loss of a tert-butyl group, and the further loss of a Gly will give a fragment ion having \( m/z \) 319. The rest of the fragment ions are different between the conjugates, indicating that there are two GSH conjugate isomers. One GSH conjugate may be formed from the addition of the oxygen to the internal carbon, and the other derived from the addition of the oxygen to the terminal carbon of ethynyl moiety. The structures cannot be ascertained from the MS/MS spectrum. Two proposed structures for the GSH conjugates with the oxygen added to the internal or terminal carbon of ethynyl moiety are shown in Fig. 8D. The fragmentation sites leading to the formation of fragment ions at \( m/z \) 376, 303, 265, 247, and 190 are indicated by dashed lines. For the conjugate eluting at 11.9 min, the loss of water from the ion at \( m/z \) 247 will form an ion at \( m/z \) 229. For the conjugate eluting at 13.5 min, the loss of water from ion at \( m/z \) 265 will form an ion at \( m/z \) 247. Again, the presence of two distinct ions at \( m/z \) 183 (B) and \( m/z \) 203 (C) indicates a structural difference between these two conjugates. The ion at \( m/z \) 203 may be caused by the loss of Glu...
and water from a fragment ion of the CH$_2$CO moiety linked to the GSH at $m/z$ 350 (Lin and Hollenberg, 2007). The ion at $m/z$ 183 is probably part of the GSH moiety. The mass increase of 142 Da, equivalent to the mass of oxygenated BMP, for the GSH-BMP conjugate is identical to the mass increase seen for the heme adducts, indicating that the same reactive species forming the GSH-BMP conjugate can also N-alkylate the pyrrole rings in the heme. Although the reactive species with oxygen added to the terminal carbon of ethynyl moiety is detected, the lack of protein modification may be the result of the absence of nucleophilic residues in the active site or their distance from the site of formation of the reactive intermediate or their reactivity.

**Discussion**

The importance of the Thr205 residue in CYP2B1 has been previously shown in studies that show it plays a role in the 16β-hydroxylation activity of testosterone and androstenedione and in the mechanism-based inactivation of CYP2B1 by 17α-ethynylestradiol (Lin et al., 2003, 2004). Here, the mechanism-based inactivation of WT CYP2B1 by two structurally related tert-butyl acetylenic compounds, BPA and BMP, and the effect of the mutation of Thr205 to Ala on the inactivation were investigated. Both BPA and BMP are very effective mechanism-based inactivators of CYP2B1. However, the efficiency of the inactivation is ~100-fold greater and the partition ratio is 10-fold less with BPA than with BMP, indicating that BPA is a more potent mechanism-based inactivator than BMP. The inactivation of CYP2B1 by BMP is a result of covalent binding of BMP to the apoprotein, and the inactivation by BMP is caused by the formation of multiple heme adducts. It is of interest to note that BMP also inactivates CYP2E1 (Blobaum et al., 2002), whereas BPA does not (H. L. Lin and P. F. Hollenberg, unpublished observation).

The mutation of Thr205 to Ala leads to a decrease in $k_{\text{inact}}$ of ~4-fold for both BMP and BPA. There is no significant change in the $K_t$ of BMP, whereas there is a dramatic increase in the $K_t$ of BPA. Thus, the mutation of Thr205 has a much more profound effect on the efficiency of inactivation ($k_{\text{inact}}/K_t$) by BPA than that by BMP. Although the T205A mutation did not change the formation of heme adduct peak 2, the formation of heme adduct peak 1 during inactivation by BMP was markedly suppressed, indicating that the regioselectivity for the N-alkylation of the pyrrole rings by the reactive oxygenated intermediate of BMP was altered by the Thr to Ala conversion.

To facilitate the interpretation of the experimental data, we constructed a CYP2B1 homology model based on the crystal structure of CYP2B4 (Scott et al., 2004). The structure of the distal surface of CYP2B1, showing the location of
Leu201, Thr205, and Phe206 in the F-helix, the location of Asn237 in the G-helix, and the location of Phe297, Glu301, and Thr302 in the I-helix, is displayed in Fig. 9. Docking studies suggest that the triple bond of BPA is positioned within the active site at an angle of $\sim 60^\circ$ and a distance of 2.96 Å from the heme iron (Fig. 9A), whereas the triple bond in BMP displays a favored orientation that is almost parallel to the heme plane (Fig. 9B). The differences between the orientations of the triple bonds in the active site may explain why protein modification is favored during inactivation by BPA, whereas heme alkylation is favored during inactivation by BMP. Both BPA and BMP have tert-butyl side chains; however, the difference between BPA and BMP is the presence of the phenyl and methyl-ether moieties, respectively. It appears that this difference has a tremendous effect on the orientation of the substrates in the active site. Residues in the active site within 3.5 Å of BPA are Ile101, Ile104, Ile114, Phe115, Phe297, Thr302, Val367, and Ile477. Residues within 3.5 Å of BMP are Arg98, Ile114, Glu301, Val363, and Val367. Shown in color are BPA and BMP (cyano), F-helix (orange), I-helix (green), heme (red), and the axial Cys436 (yellow).

Fig. 9. Homology modeling and docking studies of BPA (A) and BMP (B) into the CYP2B1 active site. Leu201, Thr205, and Phe206 are F-helix residues. Phe297, Glu301, and Thr302 are I-helix residues. Two hydrogen bonds are indicated by blue dashed lines: 1) between Thr205 and Leu201; 2) between Thr205 and Asn237. Residues within 3.5 Å of BPA are Ile101, Ile104, Ile114, Phe115, Phe297, Thr302, Val367, and Ile477. Residues within 3.5 Å of BMP are Arg98, Ile114, Glu301, Val363, and Val367. Shown in color are BPA and BMP (cyano), F-helix (orange), I-helix (green), heme (red), and the axial Cys436 (yellow).
away from the active site. As a consequence, the overall conformational change in these regions may alter both substrate access to the active site and the binding orientations of substrates within the active site. Thus, the $k_{\text{inact}}$ values for the inactivation of the mutant by both BPA and BMP were decreased. After the Thr to Ala conversion, the $K_f$ for inactivation by BPA increased ~25-fold, whereas there was no change for BMP. As shown in Fig. 9A, docking studies of BPA suggest that Phe206 is very close to Phe297 and that the three residues Phe297, Ile104, and Phe115 are close to each other. The change in the conformation of Phe206 on the replacement of Thr205 by Ala may affect the conformation of the Phe297, Ile104, and Phe115 residues and thereby alter the hydrophobic interactions between BPA and residues closest to it. However, Phe297, Ile104, and Phe115 are not in close contact with BMP (Fig. 9B). When Thr205 was substituted with Ala, the loss of stability of protein-substrate binding site caused by the interactions between residues Phe206, Phe297, Ile104, and Phe115 would be expected to have a higher impact on the binding affinity of BPA than of BMP. Therefore, it appears that the docking analyses are consistent with our experimental results.

Previous studies have shown that BMP inactivates CYP2B4 as a result of the formation of two heme adducts in which N-alkylation of pyrrole rings A and D is suggested to occur (Von Weymarn et al., 2004). Ortiz de Montellano et al. (1982) have shown the formation of three metal-free regioisomers as a result of prosthetic heme alkylation after ad- 

17

omisation. The first two isomers, which eluted very close together by HPLC, are identified as structures with the vinyl-substituted pyrrole rings (A and B). The third isomer is identified as a structure with the N-alkyl group either on the C or D ring. In this study, LC/MS/MS analysis has revealed the formation of three different Fe-free heme ad- 


ducts, suggesting that oxygenated BMP also N-alkylates three of the four pyrrole rings. The HPLC elution profile of the heme adducts formed by the inactivation of CYP2B1 by BMP is very similar to that observed for the inactivation of hepatic microsomal P450 by ethchlorvynol. The results presented here suggest that BMP destroys the CYP2B1 heme by alkylating three of the pyrrole nitrogens. Our docking studies suggest that the C ring is much more favored to be alkylated than the D ring. Thus, we postulate that rings A, B, and C were alkylated. As shown in Fig. 4, the amount of heme adduct peak 2, corresponding to alkylation of the C ring, is about the same in both WT and T205A, whereas the formation of heme adduct peak 1, corresponding to alkylation of rings A and B, is 10-fold lower in the T205A mutant than in the WT, indicating that the Thr205 to Ala conversion selec- 


tively suppressed the N-alkylation of rings A and B. Perhaps, the disruption of Thr205-Leu201 and Thr205-Asn237 hydro- 


gen bonding caused by the conversion of Thr205 to Ala may alter the conformation in the F-G region for BMP entering the substrate access channel. As a consequence, the orienta- 


tion of the BMP triple bond may be steered away from rings A and B in the heme pocket. In short, Thr205 plays an important role in the regiochemistry of heme alkylation by BMP.

In conclusion, BPA and BMP inactivate CYP2B1 very ef- 


effectively. BPA causes inactivation as a result of covalent binding of the activated BPA to the P450 apoprotein, whereas BMP causes inactivation as a result of N-alkylation of the pyrrole rings. The results presented here further show the importance of the F-Helix residues in catalysis by CYP2B1. The inactivation of CYP2B1 by BPA was caused by the formation of an adducted protein that exhibits a mass increase of 174 Da, which is equivalent to the addition of BPA plus one oxygen atom. LC/MS/MS studies that identify Thr302 as the residue covalently modified by the reactive intermediate of BPA will be presented in a subsequent publication.

Acknowledgments

We thank Dr. Ute M. Kent for suggestions, informative discus- 


sions, and continuing interest.

References


Lin HL and Hollenberg PF (2007) The inactivation of cytochrome P450 3A5 by 17α-ethynylestradiol is cytochrome β-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J Pharmacol Exp Ther 321:276–287.


Address correspondence to: Paul F. Hollenberg, Department of Pharmacology, 2301 MSRB III, 1150 West Medical Center Drive, Ann Arbor, MI 48109-5632. E-mail: phollen@umich.edu